Evidence map›Paper›PMID 27821098›Full record

ArticleBMC cancer2016

Frequency of Her2/neu expression in colorectal adenocarcinoma: a study from developing South Asian Country.

Asma Shabbir, Talat Mirza, Abdullah Bin Khalid, Muhammad Asif Qureshi, Sadaf Ahmed Asim

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. The Role of Beclin 1 and HER2 in Colorectal Carcinoma; An Immunohistochemical Study.Asian Pacific journal of cancer prevention : APJCP · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Differential Expression of HER2 and SKP2 in Benign and Malignant Colorectal Lesions.Asian Pacific journal of cancer prevention : APJCP · 2020
    Article
  12. Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020
    Review
  13. Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer.Virchows Archiv : an international journal of pathology · 2020
    Article
  14. Clinical, histopathological and immunohistochemical features of brain metastases originating in colorectal cancer: a series of 27 consecutive cases.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie · 2020
    Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Asma ShabbirSindh Medical College, Jinnah Sindh Medical University, Karachi, Pakistan. drasma52@gmail.com.
Talat MirzaDow International Medical College, Dow University of Health Sciences, Karachi, Pakistan.
Abdullah Bin KhalidDow University of Health Sciences, Karachi, Pakistan.
Muhammad Asif QureshiDow International Medical College, Dow University of Health Sciences, Karachi, Pakistan.
Sadaf Ahmed AsimDow International Medical College, Dow University of Health Sciences, Karachi, Pakistan.
Dow University of Health Sciences · PKJinnah Sindh Medical University · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman Epidermal Growth Factor (Her-2/neu) has strong therapeutic implications in certain cancers like breast and gastric cancer. Literature on its frequency in colorectal cancer is scarce. In this study, we have investigated the frequency of Her-2/neu expression in colorectal adenocarcinomas and its association with various clinicopathological variables.

methodsA total of 95 patients who underwent colonoscopic biopsy or colectomy were studied after Institutional Ethical Approval. Hematoxylin & eosin (H&E) staining was performed on all the tissue sections. Expression of Her-2/neu was investigated by immunohistochemistry using α-Her-2 antibody. In order to quantify Her-2/neu expression, three criterias were applied that includes the pattern of staining, intensity of staining and percentage of tumor cells stained. Furthermore, its association was seen with various clinicopathological variables including age, gender, histopathological type, grade and stage of the tumor. Data was entered and analyzed using SPSS version 21. A p-value of < 0.05 was considered as significant.

resultsFrom the total of 95 cases, 75 (78.9 %) cases showed Her-2/neu expression. Pattern of Her-2/neu staining was significantly associated with the grade of colorectal cancer depicting cytoplasmic Her-2/neu expression higher in low grade (50 %) while membranous Her-2/neu expression more in high grade colorectal cancer (45 %) (P-value = 0.030). Pattern of Her-2/neu staining was also significantly associated with the type of colorectal cancer representing membranous Her-2/neu expression to be more common in mucinous type (38.5 %) while cytoplasmic Her-2/neu expression to be more frequent in non mucinous type (42.7 %) of colorectal cancer (p-value = 0.024). We observed a significant association between percentage of cells stained & tumor type, with score 3+ maximum in non mucinous type of colorectal cancer (p-value = 0.006).

conclusionHer2/neu is considerably expressed in colorectal adenocarcinoma in Pakistani population. Our findings indicate a significant strong association of cytoplasmic Her-2/neu expression with low grades and membranous Her-2/neu expression with high grades of colorectal cancer. These findings add to the body of information & may help in conducting clinical trials in future to explore its therapeutic significance as well.

Indexed as

Gene ExpressionAdenocarcinomaAdultAgedAged, 80 and overAsia, SoutheasternBiopsyColorectal NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansImmunohistochemistryMaleMiddle AgedNeoplasm GradingYoung AdultERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesColorectal adenocarcinomaHer-2/neuImmunohistochemistryTrastuzumab

Identifiers

PMID27821098
PMCPMC5100101
OpenAlexW2556836317

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.